Obesity
Conditions
Interventions
Diet Group:Limit your diet to 1500 kcal/d (25% protein, 30% fat, 45% carbohydrates) or follow a ketogenic diet for one month for monitoring
Sports Group:Moderate-intensity prescription exercise: 5 days a week, 30 minutes per day for 1 month. Real-time monitoring by smart bracelet + check-in monitoring
Weight-loss drugs group:Tirzepatide subcutaneous injection starts at 2.5 mg/w, titrated to 10 mg/w, one-month electronic medication diary. Pharmacological interventions are tailored to the specific dr
Wiring assembly:The operation video of acupoint embedding once every two weeks for one month should be archived
Acupuncture Group:Electroacupuncture treatment was administered once a week for one month, the same as the suture group
Weight loss tea set:Take 2 packs of formula tea every day for 1 month. Count the tea bags and monitor the check-in video
Gastric bypass stent group:Archived records of single intervention surgeries for endoscopic implantation of absorbable stents
Surgical Group:Single intervention for sleeve gastrectomy laparoscopic surgery or robotic surgery shall be carried out in accordance with the ‘‘Surgical Guidelines for Obesity’’
Sponsors
Shandong Provincial Third Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Intervention group: 1. Aged 18-60 years, BMI>=24 kg/m^2; 2. Or for men: Waist circumference >= 90 cm; for women: waist circumference >= 85 cm; 3. Meet the medical application criteria for at least one intervention method (for example, the surgical group needs to comply with the ICD guidelines); 4. Voluntarily sign the informed consent form. Control group: 1. Aged 18 to 60 years old, BMI: 18.5 <= BMI < 24kg/m^2; 2. Voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Secondary obesity (e.g., Cushing's syndrome, hypothalamic obesity, etc.); 2. Severe cardiovascular diseases (NYHA Class III–IV, myocardial infarction/stroke within the past 6 months); 3. Uncontrolled hypertension (SBP >= 180 mmHg or DBP >= 110 mmHg); 4. Hepatic or renal insufficiency; 5. Contraindications to bariatric surgery (ASA Class IV, coagulation disorders); 6. Pregnancy or planned pregnancy; 7. Conditions deemed by the investigator as requiring exclusion; 8. Diseases unsuitable for dietary or exercise interventions, such as cardiac diseases or bone/joint disorders; 9. Diseases unsuitable for participation in this study; 10. Visual or auditory impairments affecting cognitive assessments; 11. Contraindications to the use of weight-loss medications such as tirzepatide; 12. Contraindications to traditional Chinese medicine treatments such as catgut embedding or acupuncture.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The decrease in BMI from baseline at 1 month of intervention (%); ;Improvement in HOMA-IR; | — |
Secondary
| Measure | Time frame |
|---|---|
| The decrease in LDL-C;Dynamic changes in resting metabolic rate;Number of differential metabolites;Changes in microbial diversity;Comprehensive efficacy level; | — |
Countries
China
Contacts
Public ContactPeng Fu
Shandong Provincial Third Hospital
Outcome results
None listed